For example, in IBD immunocompromised patients, a reduced/lack of IL-2 activity could impair immune surveillance by antineoplastic lymphokine-activated killer or natural killer cells and may result in a higher risk for IBD-associated colorectal cancer. The gene discussed is IL2; the disease is irritable bowel syndrome.